Patent Law Weblog
recent posts
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
- United States Files Statement of Interest in Patent Infringement Proceedings
about
Month: February 2012
-
By Kwame Mensah — Last month, Castle Biosciences Inc., a Friendswood, Texas-based corporation specializing in rare cancer molecular diagnostics, announced that it had acquired an exclusive worldwide license to intellectual property covering a gene expression profiling test for thymoma, which is a rare tumor derived from the epithelial cells of the thymus gland. Castle Biosciences…
-
By Kevin E. Noonan — Dr. Ellen Jorgensen of Genspace, one of the witnesses at the U.S. Patent and Trademark Office's first hearing regarding the advisability of permitting "second opinions" for patented genetic diagnostic tests without patent infringement liability, advocated "at-home" or "do-it-yourself" DNA testing as a solution (see "USPTO Holds First Hearing on 'Second…
-
By Donald Zuhn — USPTO Leadership to Host Webinar on Tuesday The U.S. Patent and Trademark Office announced last week that senior agency officials would be hosting a free public webinar on Tuesday, February 21 at 4:30 pm (ET). The webinar will be moderated by Peter Pappas, Chief of Staff for the Office of the…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases. Merck & Cie et al. v. Watson Pharmaceuticals, Inc. et al.2:12-cv-00223; filed February 13, 2012 in the District Court of Nevada • Plaintiffs: Merck & Cie; Bayer Pharma AG; Bayer Healthcare Pharmaceuticals Inc.• Defendants: Watson…
-
February 21, 2012 – The New Inter Partes Proceedings at the USPTO — The Preliminary Phase: Filing a Petition, the Preliminary Response, and Institution of Review (Intellectual Property Owners Association) – 2:00 – 3:00 pm (ET) February 21-22, 2012 – Biotech & Pharmaceutical Patenting*** (IBC Legal) – Munich, Germany February 21, 2012 – The New…
-
American Conference Institute (ACI) will be holding its next Paragraph IV Disputes conference on April 24-25, 2012 in New York, NY. The conference will allow attendees to: • Assess how Patent Reform will influence Orange Book Patent challenges and pre-suit considerations;• Refine Markman hearing strategies in view of the Federal Circuit split on claim construction;•…
-
The Intellectual Property Owners Association (IPO) will offer a two one-hour webinars on "The New Inter Partes Proceedings at the USPTO" on Wednesday, February 21, 2012 and Thursday, February 22, 2012, with each session beginning at 2:00 pm (ET). On February 21, a panel consisting of the Hon. Michael Tierney of the U.S. Patent &…
-
By Kevin E. Noonan — The U.S. Patent and Trademark Office held the first of two planned hearings aimed at fulfilling one of the reporting provisions of the Leahy-Smith America Invents Act (see "USPTO to Hold Hearing on Genetic Diagnostic Testing"). Section 27 of the Act requires the Office to conduct a study regarding…
-
Patent Docs author Dr. Kevin Noonan (at right) gave the following testimony at today's USPTO hearing on genetic diagnostic testing: I want to thank the organizers for inviting me to testify today. This study by the PTO is important because it should give the Office the opportunity to determine whether there is any evidence that…
-
By Donald Zuhn — Last week, Forbes reported that the development costs for an average drug (produced by a major pharmaceutical company) are at least $4 billion, and as much as $11 billion ("The Truly Staggering Cost Of Inventing New Drugs"). The article, by Forbes science and medicine writer Matthew Herper, notes that the drug…
Patent Docs 